Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_assertion type Assertion NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_head.
- NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_assertion description "[In patients with stage III, peritoneal recurrence-free survival rates (PRFS) and overall survival rates (OS) of CD44 mRNA+ or CEA mRNA+ patients were significantly worse than those of marker genenegative patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_provenance.
- NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_assertion evidence source_evidence_literature NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_provenance.
- NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_assertion SIO_000772 21331451 NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_provenance.
- NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_assertion wasDerivedFrom befree-20140225 NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_provenance.
- NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_assertion wasGeneratedBy ECO_0000203 NP372940.RAOYUnEjnq5OeoKGfYs5SsQGOXT4SKz-pCnuPB3jWdY-A130_provenance.